KNSA Q1 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+50.2% YoY

Gross Profit

$32M66.0% margin

Operating Income

-$11M-23.2% margin

Net Income

-$12M-25.4% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-21.9%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$443M

Total Liabilities

$53M

Stockholders' Equity

$390M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$32M	+50.2%
Gross Profit	$32M	$19M	+71.3%
Operating Income	-$11M	-$23M	+52.0%
Net Income	-$12M	-$25M	+51.3%

Revenue Segments

Product

$43M88%

Collaboration

$6M12%